BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample

China Meheco Group (600056.SH): Ganciclovir for Injection Passes Generic Drug Consistency Evaluation

China Meheco Group Reports 139,689 Shareholders as of September 30, 2025

CITIC Securities: Chinese Pharma Firms Actively Explore Diversified Global Expansion, Focusing on New Growth and Industry M&A

Golden Eagle Fund: China's Pharmaceutical Industry Upgrade Continues, Focus on Three Investment Opportunities

Guo Guangchang: Original Innovation is the Inevitable Path for China's Pharmaceutical Industry, Open Collaboration is the Best Way to Accelerate Innovation

China Meheco Group Upgraded to 'A' Rating in ESG Performance

Breakthrough Record: China Medical's Largest Offshore Deal Exceeds 80 Billion

China Approves Meheco Supplementary Application for Vitamin B6 Injection

Yonyou Network (600588) Wins Procurement Project from China Meheco Group Co., Ltd. with a Bid Amount of 4.3 Million Yuan

IPO News | Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Pursues Hong Kong Stock Exchange Listing, Maintains 8-Year Streak on "China's Top 100 Pharmaceutical Companies" List

BOCOM International: Trump's Drug Tariffs Have Limited Impact on Chinese Pharmaceuticals, Recommends Focus on AKESO (09926) and Others

China Meheco's Unit Gets Nod for Supplementary Application for Lincomycin Hydrochloride Injection After Passing Evaluation

China Meheco Group's Subsidiary Receives Approval for Lincomycin Hydrochloride Injection Generic Drug Consistency Evaluation

Medical E-commerce Concept Stocks Surge in Afternoon Trading, China Meheco Group Hits Daily Limit Up

Jin Ying Fund's Ouyang Juan: China's Pharmaceutical Industry Upgrade Continues to Deliver, Focus on Innovative Drugs and Supply Chain

China Merchants International: Chinese Pharmaceutical Stocks Expected to Continue Rising on Innovation Drug Overseas Expansion and Domestic Policy Optimization, Recommends Buying 3SBIO (01530) and Others

China's Medical Device Import and Export Totaled $41.09 Billion in H1 2025, Up 1.1% YoY

Chinese Pharmaceuticals Ascend Global Stage! In This Value Revaluation Era, Who Will Dominate Investment Heights?

CCB International Maintains Cautious Optimism on Chinese Pharmaceutical Stocks Despite High Valuations, Assigns "Outperform" Rating to BeiGene (06160)